Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

In vitro comparative models for canine and human breast cancers.

Visan S, Balacescu O, Berindan-Neagoe I, Catoi C.

Clujul Med. 2016;89(1):38-49. doi: 10.15386/cjmed-519. Epub 2016 Jan 15. Review.

2.

Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis.

Demehri S, Cunningham TJ, Manivasagam S, Ngo KH, Moradi Tuchayi S, Reddy R, Meyers MA, DeNardo DG, Yokoyama WM.

J Clin Invest. 2016 Apr 1;126(4):1458-70. doi: 10.1172/JCI83724. Epub 2016 Feb 29.

PMID:
26927668
3.

Application of imaging mass spectrometry for the molecular diagnosis of human breast tumors.

Mao X, He J, Li T, Lu Z, Sun J, Meng Y, Abliz Z, Chen J.

Sci Rep. 2016 Feb 12;6:21043. doi: 10.1038/srep21043.

4.

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.

Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.

Pigment Cell Melanoma Res. 2016 May;29(3):317-28. doi: 10.1111/pcmr.12465. Epub 2016 Mar 21.

PMID:
26850518
5.

Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast, Colorectal, and Prostate Cancer: A Systematic Review.

Martin F, Ufodiama C, Watt I, Bland M, Brackenbury WJ.

Front Pharmacol. 2015 Nov 12;6:273. doi: 10.3389/fphar.2015.00273. eCollection 2015. Review.

6.

Digital histologic analysis reveals morphometric patterns of age-related involution in breast epithelium and stroma.

Sandhu R, Chollet-Hinton L, Kirk EL, Midkiff B, Troester MA.

Hum Pathol. 2016 Feb;48:60-8. doi: 10.1016/j.humpath.2015.09.031. Epub 2015 Oct 23.

PMID:
26772400
7.

Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.

Liu Y, Yin T, Feng Y, Cona MM, Huang G, Liu J, Song S, Jiang Y, Xia Q, Swinnen JV, Bormans G, Himmelreich U, Oyen R, Ni Y.

Quant Imaging Med Surg. 2015 Oct;5(5):708-29. doi: 10.3978/j.issn.2223-4292.2015.06.01. Review.

8.

Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome.

Xu C, Wang Z, Cui R, He H, Lin X, Sheng Y, Zhang H.

BMC Cancer. 2015 Nov 23;15:925. doi: 10.1186/s12885-015-1873-x.

9.

Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development.

Aswad L, Yenamandra SP, Ow GS, Grinchuk O, Ivshina AV, Kuznetsov VA.

Oncotarget. 2015 Nov 3;6(34):36652-74. doi: 10.18632/oncotarget.5543.

10.

RelA-Induced Interferon Response Negatively Regulates Proliferation.

Kochupurakkal BS, Wang ZC, Hua T, Culhane AC, Rodig SJ, Rajkovic-Molek K, Lazaro JB, Richardson AL, Biswas DK, Iglehart JD.

PLoS One. 2015 Oct 13;10(10):e0140243. doi: 10.1371/journal.pone.0140243. eCollection 2015.

11.

Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset.

Gunaydin G, Kesikli SA, Guc D.

Oncoimmunology. 2015 May 27;4(9):e1034918. eCollection 2015 Sep.

PMID:
26405600
12.

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2015 Sep 1;10(9):e0136851. doi: 10.1371/journal.pone.0136851. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0151121.

13.

Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents.

Garrison JB, Ge C, Che L, Pullum DA, Peng G, Khan S, Ben-Jonathan N, Wang J, Du C.

J Cancer Sci Ther. 2015 Apr;7(4):121-126.

14.

The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Ochieng J, Nangami GN, Ogunkua O, Miousse IR, Koturbash I, Odero-Marah V, McCawley LJ, Nangia-Makker P, Ahmed N, Luqmani Y, Chen Z, Papagerakis S, Wolf GT, Dong C, Zhou BP, Brown DG, Colacci AM, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Amedei A, Al-Temaimi R, Al-Mulla F, Bisson WH, Eltom SE.

Carcinogenesis. 2015 Jun;36 Suppl 1:S128-59. doi: 10.1093/carcin/bgv034. Review.

PMID:
26106135
15.

A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment.

Anastasov N, Höfig I, Radulović V, Ströbel S, Salomon M, Lichtenberg J, Rothenaigner I, Hadian K, Kelm JM, Thirion C, Atkinson MJ.

BMC Cancer. 2015 Jun 10;15:466. doi: 10.1186/s12885-015-1481-9.

16.

Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness.

Lee NS, Evgrafov OV, Souaiaia T, Bonyad A, Herstein J, Lee JY, Kim J, Ning Y, Sixto M, Weitz AC, Lenz HJ, Wang K, Knowles JA, Press MF, Salvaterra PM, Shung KK, Chow RH.

Sci Rep. 2015 Jun 8;5:11207. doi: 10.1038/srep11207.

17.

53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.

Kong X, Ding X, Li X, Gao S, Yang Q.

Cancer Sci. 2015 Aug;106(8):982-9. doi: 10.1111/cas.12699. Epub 2015 Jul 14.

18.

Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk.

De Melo J, Tang D.

PLoS One. 2015 May 19;10(5):e0127546. doi: 10.1371/journal.pone.0127546. eCollection 2015.

19.

OncoRep: an n-of-1 reporting tool to support genome-guided treatment for breast cancer patients using RNA-sequencing.

Meißner T, Fisch KM, Gioia L, Su AI.

BMC Med Genomics. 2015 May 21;8:24. doi: 10.1186/s12920-015-0095-z.

20.

Estradiol induces HOTAIR levels via GPER-mediated miR-148a inhibition in breast cancer.

Tao S, He H, Chen Q.

J Transl Med. 2015 Apr 25;13:131. doi: 10.1186/s12967-015-0489-x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk